Results about: iproteos

IRB Barcelona presents its technology and capacities at the 2017 BIO International Convention

IRB Barcelona, along with another 30 Catalan companies and organisations, is participating in the four-day convention in San Diego.

The BIO International Convention (BIO) is the top partnering fair for the biomedical sector.

The Institute’s spin-offs Iproteos and Nostrum Biodiscovery are also visiting the fair.

IRB Barcelona’s Innovation Department is ready for partnering at BIO-Europe Spring 2017

The 11th international partnering conference comes to Barcelona from 20 to 22 March.

19 young researchers at IRB Barcelona will also be attending the three-day conference.

BIO-Europe Spring is the premier springtime partnering conference for the biotechnology industry.

A study reveals the effectiveness of a cognitive enhancer for schizophrenia treatment

Compound IPR19, a drug to stop the progression and reverse the cognitive deficits associated with schizophrenia.

Iproteos closes a round of funding valued at 1.5 million Euros

The biotech will set aside this injection of capital –led by Caixa Capital Risc- to complete the preclinical phase in order to start Human Phase I trials of its compound to the treatment of Cognitive Impairment Associated with Schizophrenia. The drug is one of the few under development worldwide to halt the progression and reverse the symptoms of this condition.

The drug is a first-in-class for the treatment of Cognitive Impairment Associated with Schizophrenia  (CIAS). The compound has been developed using their proprietary IPROTech, a cutting-edge platform the fast and cost-effectively obtaining of innovative drugs.  

Iproteos, settled at the Parc Cientific de Barcelona, is a spin-off created in 2011 by two Catalan leading scientists in the field of therapeutic peptides, Teresa Tarragó and Ernest Giralt, based on the technology transfer from IRB Barcelona and the University of Barcelona.

European project to develop an innovative therapeutic strategy against epilepsy

The European project «ECMED» (acronym of Extracellular Matrix in Epileptogenesis) is aimed to design, validate and bring into practice new innovative therapeutic strategies to further the development of a treatment and a diagnostic approach for the management of epilepsy.

The project, which has a duration of three years and a budget of € 3.5 million, is co-funded by the European Union within the Horizon 2020 research and innovation framework program through a Marie Sklodowska-Curie grant.

Biotech Iproteos, –an spin-off the IRB Barcelona and the University of Barcelona, based at Parc Científic de Barcelona– is the only Spanish partner of the consortium.